.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Argus Health
Colorcon
Moodys
QuintilesIMS
AstraZeneca
UBS
Fish and Richardson
Farmers Insurance
US Department of Justice

Generated: December 18, 2017

DrugPatentWatch Database Preview

ZOMIG Drug Profile

« Back to Dashboard

Which patents cover Zomig, and what generic alternatives are available?

Zomig is a drug marketed by Astrazeneca and IPR and is included in three NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in ZOMIG is zolmitriptan. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
AstrazenecaZOMIGzolmitriptanSPRAY;NASAL021450-003Sep 16, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
IprZOMIGzolmitriptanTABLET;ORAL020768-001Nov 25, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe
AstrazenecaZOMIGzolmitriptanSPRAY;NASAL021450-004Sep 30, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
IprZOMIGzolmitriptanTABLET;ORAL020768-002Nov 25, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe
AstrazenecaZOMIGzolmitriptanSPRAY;NASAL021450-003Sep 16, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
AstrazenecaZOMIGzolmitriptanSPRAY;NASAL021450-003Sep 16, 2013RXYesNo► Subscribe► Subscribe► Subscribe
AstrazenecaZOMIGzolmitriptanSPRAY;NASAL021450-004Sep 30, 2003RXYesYes► Subscribe► Subscribe► Subscribe
AstrazenecaZOMIGzolmitriptanSPRAY;NASAL021450-004Sep 30, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
AstrazenecaZOMIG-ZMTzolmitriptanTABLET, ORALLY DISINTEGRATING;ORAL021231-002Sep 17, 2001ABRXYesYes► Subscribe► Subscribe► Subscribe
AstrazenecaZOMIG-ZMTzolmitriptanTABLET, ORALLY DISINTEGRATING;ORAL021231-001Feb 13, 2001ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZOMIG

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
IprZOMIGzolmitriptanTABLET;ORAL020768-001Nov 25, 1997► Subscribe► Subscribe
AstrazenecaZOMIGzolmitriptanSPRAY;NASAL021450-004Sep 30, 2003► Subscribe► Subscribe
IprZOMIGzolmitriptanTABLET;ORAL020768-002Nov 25, 1997► Subscribe► Subscribe
IprZOMIGzolmitriptanTABLET;ORAL020768-002Nov 25, 1997► Subscribe► Subscribe
IprZOMIGzolmitriptanTABLET;ORAL020768-001Nov 25, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ZOMIG

Drugname Dosage Strength RLD Submissiondate
zolmitriptanNasal Spray2.5 mg/sprayZomig6/9/2016
zolmitriptanNasal Spray5 mg/sprayZomig11/14/2013

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Covington
Harvard Business School
Moodys
Farmers Insurance
Johnson and Johnson
Cantor Fitzgerald
Deloitte
Chinese Patent Office
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot